The NHance
18F-FDG-PET/CT
MET
antibody
cancer
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
10 Jun 2021
10 Jun 2021
Historique:
received:
06
04
2021
revised:
27
05
2021
accepted:
08
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Dysregulation of MET signaling has been implicated in tumorigenesis and metastasis. ARGX-111 combines complete blockade of this pathway with enhanced tumor cell killing and was investigated in 24 patients with MET-positive advanced cancers in a phase 1b study at four dose levels (0.3-10 mg/kg). ARGX-111 was well tolerated up to 3 mg/kg (MTD). Anti-tumor activity was observed in nearly half of the patients (46%) with a mean duration of treatment of 12 weeks. NHance
Identifiants
pubmed: 34200749
pii: biomedicines9060665
doi: 10.3390/biomedicines9060665
pmc: PMC8229762
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cells. 2020 Feb 24;9(2):
pubmed: 32102486
J Clin Oncol. 2011 Dec 20;29(36):4803-10
pubmed: 22042947
Oncotarget. 2017 Jun 13;8(24):38193-38213
pubmed: 28445144
J Histochem Cytochem. 2017 Jun;65(6):321-333
pubmed: 28402755
J Control Release. 2016 Feb 10;223:42-52
pubmed: 26718855
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
pubmed: 18093943
J Cancer Res Ther. 2015 Aug;11 Suppl 1:C63-7
pubmed: 26323927
Clin Chem Lab Med. 2019 Jul 26;57(8):1142-1152
pubmed: 31112502
Cancer Discov. 2013 Jun;3(6):658-73
pubmed: 23729478
Nat Rev Cancer. 2002 Apr;2(4):289-300
pubmed: 12001990
Cell Cycle. 2014;13(24):3808-17
pubmed: 25426675
J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47
pubmed: 9262252
J Med Chem. 2014 Jun 12;57(11):4427-53
pubmed: 24320965
Expert Opin Ther Targets. 2012 Jun;16(6):553-72
pubmed: 22530990
Sci Signal. 2014 Apr 22;7(322):ra38
pubmed: 24757178
Sci Signal. 2009;2(102):er11
pubmed: 20039471
J Thorac Oncol. 2016 Aug;11(8):1293-1304
pubmed: 27262212
J Hematol Oncol. 2016 Dec 7;9(1):135
pubmed: 27923392
Clin Cancer Res. 2017 Nov 1;23(21):6411-6420
pubmed: 28765328
PLoS One. 2015 Oct 07;10(10):e0139679
pubmed: 26445503
Clin Cancer Res. 2017 Feb 15;23(4):992-1000
pubmed: 27573171
J Clin Pharmacol. 2013 Feb;53(2):192-201
pubmed: 23436264
J Nucl Med. 2008 Jan;49(1):129-134
pubmed: 18077531
Eur J Cancer. 2017 Dec;87:131-139
pubmed: 29145039
Br J Cancer. 2011 Sep 6;105(6):807-13
pubmed: 21847121
Clin Cancer Res. 2013 Feb 1;19(3):571-85
pubmed: 23236214
J Clin Oncol. 2013 Dec 10;31(35):4445-52
pubmed: 24127447
Biol Blood Marrow Transplant. 2016 Mar;22(3):456-61
pubmed: 26524732
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18709-14
pubmed: 17116867
Immunol Res. 2002;25(2):97-113
pubmed: 11999172
Blood. 2015 Mar 19;125(12):1883-9
pubmed: 25605368
J Biol Chem. 2003 Jan 31;278(5):3466-73
pubmed: 12427744
Thorac Cancer. 2017 Sep;8(5):417-422
pubmed: 28590585
Nat Med. 2016 Feb;22(2):194-201
pubmed: 26779812
Int Immunol. 2006 Dec;18(12):1759-69
pubmed: 17077181
PLoS One. 2016 Jan 14;11(1):e0146784
pubmed: 26765781
Mol Cancer Res. 2016 Jun;14(6):539-47
pubmed: 26951228
Blood. 2013 Nov 14;122(20):3482-91
pubmed: 24106207
Cancer Res. 2010 Apr 15;70(8):3269-77
pubmed: 20354184
Cancer Res. 2015 Aug 15;75(16):3373-83
pubmed: 26141862
Exp Hematol. 2009 Mar;37(3):309-21
pubmed: 19218011
J Immunol. 2007 Oct 1;179(7):4580-8
pubmed: 17878355
J Clin Invest. 2014 Jul;124(7):3172-86
pubmed: 24865428
J Clin Oncol. 2009 Apr 1;27(10):1667-74
pubmed: 19255323
Exp Mol Med. 2017 Mar 24;49(3):e307
pubmed: 28336955
MAbs. 2011 Sep-Oct;3(5):422-30
pubmed: 22048693